Related Experiment Video
Updated: Mar 5, 2026
Laparoscopy-endoscopy Cooperative Surgery for the Treatment of Gastric Gastrointestinal Stromal Tumors
Published on: February 19, 2022
Management of Gastrointestinal Stromal Tumors
Emily Z Keung1, Chandrajit P Raut2
1Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1484, Houston, TX 77030, USA.
Abstract:
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasm of the gastrointestinal tract. The stomach is the most common site of origin. Management of GISTs changed after the introduction of molecularly targeted therapies. Although the only potentially curative treatment of resectable primary GISTs is surgery, recurrence is common. Patients with primary GISTs at intermediate or high risk of recurrence should receive imatinib postoperatively. Imatinib is also first-line therapy for advanced disease. Cytoreductive surgery might be considered in advanced GIST for patients with stable/responding disease or limited focal progression on tyrosine kinase inhibitor therapy. GIST requires multidisciplinary management.
Insights
Gastrointestinal stromal tumors (GISTs), the most common GI mesenchymal neoplasms, are best managed with surgery and targeted therapies like imatinib, especially for high-risk or advanced cases. Multidisciplinary care is crucial for optimal patient outcomes.
Area of Science:
- Gastroenterology
- Oncology
- Surgical Oncology
Background:
- Gastrointestinal stromal tumors (GISTs) represent the most frequent mesenchymal neoplasms within the gastrointestinal tract.
- The stomach is the predominant site of origin for these tumors.
- The advent of molecularly targeted therapies has significantly altered GIST management paradigms.
Purpose of the Study:
- To outline the current management strategies for GISTs.
- To emphasize the role of surgery and targeted therapies in GIST treatment.
- To highlight the importance of risk stratification and multidisciplinary care.
Main Methods:
- Review of current literature and clinical guidelines for GIST management.
- Discussion of surgical resection as the primary curative modality for resectable GISTs.
- Evaluation of imatinib as a key targeted therapy for adjuvant and advanced GIST treatment.
Main Results:
- Surgery remains the only potentially curative option for resectable primary GISTs, though recurrence is a significant concern.
- Postoperative imatinib is recommended for patients with intermediate or high recurrence risk.
- Imatinib serves as the first-line therapy for advanced GIST, with cytoreductive surgery considered in select cases.
Conclusions:
- Effective GIST management necessitates a multidisciplinary approach, integrating surgical expertise with targeted medical therapies.
- Risk stratification is essential for guiding adjuvant imatinib therapy decisions.
- Advanced GIST management may involve a combination of tyrosine kinase inhibitors and, in specific scenarios, cytoreductive surgery.
Related Concept Videos
01:21Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
01:25Peptic Ulcer Disease V: Surgical Management and Nursing Care
Surgical Interventions for Peptic Ulcer Disease
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...